Ublituximab Bests Teriflunomide in Relapsing Multiple Sclerosis
WEDNESDAY, Aug. 31, 2022 (HealthDay News) -- Patients with relapsing multiple sclerosis receiving ublituximab have lower annualized relapse rates and fewer brain lesions on magnetic resonance imaging than those receiving teriflunomide, according to a study published in the Aug. 25 issue of the New England Journal of Medicine.
Lawrence Steinman, M.D., from Stanford University in California, and colleagues conducted two identical, double-blind trials (ULTIMATE I and ULTIMATE II) involving participants with relapsing multiple sclerosis who were randomly assigned to receive either intravenous ublituximab and oral placebo or oral teriflunomide and intravenous placebo. A total of 549 and 545 participants were enrolled in the ULTIMATE I and ULTIMATE II trials, respectively, and were followed for a median of 95 weeks.
The researchers found that the annualized relapse rate was 0.08 with ublituximab and 0.19 with teriflunomide in the ULTIMATE I trial (rate ratio, 0.41) and was 0.09 and 0.18, respectively, in the ULTIMATE II trial (rate ratio, 0.51). In the ULTIMATE I trial, the mean number of gadolinium-enhancing lesions was 0.02 in the ublituximab group and 0.49 in the teriflunomide group (rate ratio, 0.03). In the ULTIMATE II trial, the numbers were 0.01 and 0.25, respectively (rate ratio, 0.04). In a pooled analysis of the trials, worsening of disability at 12 weeks did not differ significantly between the groups and occurred in 5.2 percent of participants receiving ublituximab and 5.9 percent of participants receiving teriflunomide. Infusion-related reactions were reported in 47.7 percent of participants receiving ublituximab.
"Larger and longer trials are required to determine the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis, including comparison with other disease-modifying treatments such as existing anti-CD20 monoclonal antibodies," the authors write.
The study was funded by TG Therapeutics, the manufacturer of ublituximab.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Walmart Offers $3 Billion to Settle Opioid Lawsuits
TUESDAY, Nov. 15, 2022 (HealthDay News) -- Another major pharmacy chain has...
Health Highlights: Oct. 18, 2021
How 1.3 million Americans ended up in conservatorships. Britney Spears' long...
Use of Wearable Devices Low for Those With Cardiovascular Disease Risk
FRIDAY, June 9, 2023 (HealthDay News) -- Less than one in four U.S. adults with...
Una de cada seis personas sin vacunar se enfrentan a síntomas dos años tras tener COVID
VIERNES, 2 de junio de 2023 (HealthDay News) -- Las personas sin vacunar con...